Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?

American Diabetes Association (2008) 2008 Clinical Practice Recommendations. Diabetes Care 31(Suppl. 1): S27–S28.

American Diabetes Association (2009) 2009 Clinical Practice Recommendations. Diabetes Care 32(Suppl. 1): S31–S32.

American Diabetes Association (2010) 2010 Clinical Practice Recommendations. Diabetes Care 33(Suppl. 1): S32–S33.

Angiolillo D.J. . (2009) Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32: 531–540.

Antithrombotic Trialists’ Collaboration. (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86.

Antithrombotic Trialists’ Collaboration. (2009) Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849–1860.

Belch J. MacCuish A. Campbell I. Cobbe S. Taylor R. Prescott R. . (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840–a1840.

Bhattacharyya O.K. Shah B.R. Booth G.L. . (2008) Management of cardiovascular disease in patients with diabetes: The 2008 Canadian Diabetes Association guidelines. CMAJ 179: 920–926.

Davì G. Santilli F. . (2010) Aspirin as antiplatelet agent in diabetes. PROS-. Eur J Intern Med 21: 149–153.

De Berardis G. Sacco M. Evangelista V. Filippi A. Giorda C.B. Tognoni G. . (2007) Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8: 21–21.

De Berardis G. Sacco M. Strippoli G.F. Pellegrini F. Graziano G. Tognoni G. . (2009) Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ 339: b4531–b4531.

Evangelista V. Totani L. Rotondo S. Lorenzet R. Tognoni G. De Berardis G. . (2005) Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. Thromb Haemost 93: 8–16.

Hernández-Díaz S. García Rodríguez L.A. . (2006) Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 4: 22–22.

Juutilainen A. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. . (2008) Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 31: 714–719.

King H. Aubert R.E. Herman W.H. . (1998) Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431.

McQuaid K.R. Laine L. . (2006) Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119: 624–638.

Ogawa H. Nakayama M. Morimoto T. Uemura S. Kanauchi M. Doi N. . (2008) Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 300: 2134–2141.

Pignone M. Alberts M.J. Colwell J.A. Cushman M. Inzucchi S.E. Mukherjee D. . (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 33: 1395–1402.

Ridker P.M. Cook N.R. Lee I.M. Gordon D. Gaziano J.M. Manson J.E. . (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293–1304.

Sacco M. Pellegrini F. Roncaglioni M.C. Avanzini F. Tognoni G. Nicolucci A. . (2003) PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26: 3264–3272.

SIGN (2010) Management of Diabetes. Publication No. 116. Edinburgh: Scottish Intercollegiate Guidelines Network. http://www.sign.ac.uk/guidelines/fulltext/116/index.html [accessed13 October 2010].

Teramoto T. Shimada K. Uchiyama S. Sugawara M. Goto Y. Yamada N. . (2010) Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP) – a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J 159: 361–369.

Turnbull F.M. Abraira C. Anderson R.J. Byington R.P. Chalmers J.P. Duckworth W.C. . (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52: 2288–2298.

Zhang C. Sun A. Zhang P. Wu C. Zhang S. Fu M. . (2010) Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 87: 211–218.